



ATTORNEY DOCKET NO. 07043/015007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : M. Allen Northrup et al.
Serial No.: 08/900,735
Filed : 07/24/1997
Title : MICROFABRICATED REACTOR

Art Unit: 1634
Examiner: Sisson, B.

Assistant Commissioner for Patents
Washington, DC 20231

DECLARATION UNDER 37 CFR § 1.131

I, Richard M. White, declare as follows:

1. I am a coinventor of the invention described in the claims of the above-identified patent application, as amended by the Response filed herewith.
2. Prior to May 1, 1992, Dr. M. Allen Northrup ("Dr. Northrup") and I completed the conception of the invention in this country as evidenced by the following:
 - Prior to May 1, 1992, Dr. Northrup and I wrote an Invention Disclosure Statement entitled "Microinstrumentation-based Polymerase Chain Reaction (PCR) Diagnostics" (Exhibit A). The Invention Disclosure Statement describes the features of an instrument for amplifying a preselected polynucleotide in a sample. This instrument included a reaction chamber and at least one reactant chamber, at least one channel interconnecting the reaction and reactant chambers, a heater configured to heat reactants in the reaction chamber, a temperature controller coupled to the heater and configured to control the temperature of a reaction in the reaction chamber, and a product analysis chamber coupled to the reaction chamber and adapted to analyze reaction products contained in the product analysis chamber, as recited in independent claims 1 and 104 of the above-identified application.

3. Dr. Northrup and I worked on the invention with due diligence in this country until the invention was reduced to practice prior to May 1, 1992, as evidenced by the following:

- In a notebook I kept, an entry (Exhibit B) dated before May 1, 1992, describes planned operational tests on a PCR instrument ("instrument A") that embodies each of the features recited in independent claims 1 and 104, and was constructed and tested prior to May 1, 1992.

- In a notebook kept by Dr. Northrup, an entry (Exhibit C) dated before May 1, 1992, describes the results of certain operational tests on instrument A. In particular, instrument A was successfully operated to amplify a preselected nucleotide.

- In the above-mentioned notebook kept by Dr. Northrup, an entry (Exhibit D) dated before May 1, 1992, contains a description of another instrument ("instrument B") that embodies each of the features recited in independent claims 1 and 104, and was constructed and tested prior to May 1, 1992.

- In the above-mentioned notebook kept by Dr. Northrup, an entry (Exhibit E) dated before May 1, 1992, describes the results of certain operational tests on instrument B. In particular, instrument B was successfully operated to amplify a preselected nucleotide.

4. Each of the dates deleted from Exhibits A-E is prior to May 1, 1992.

5. I hereby declare that all statements made of our own knowledge are true and that all statements made on information and belief are believed to be true. I understand that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. § 1001) and may jeopardize the validity of the application or any patent issuing thereon.

Date: 12 July 1999 Richard M. White
Richard M. White



PATENT

ATTORNEY DOCKET NO. 07043/015007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : M. Allen Northrup et al.
Serial No.: 08/900,735
Filed : 7/24/1997
Title : MICROFABRICATED REACTOR

Art Unit: 1634
Examiner: Sisson, B.

Assistant Commissioner for Patents
Washington, DC 20231

EXHIBITS FOR DECLARATION OF RICHARD M. WHITE

Date of Deposit

7/12/99

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Shei Wysocki
SHEI WYSOCKI

A

Invention Disclosure Statement

Title: Microinstrumentation-based Polymerase Chain Reaction (PCR) Diagnostics

Inventors:

M. Allen Northrup
923 Creston Rd
Berkeley, CA 94708

Richard M. White
350 Panoramic Rd
Berkeley, CA 94708

Date:

Background:

The polymerase chain reaction (PCR) is a method by which a single molecule of DNA (or RNA) of an organism can be selectively amplified several millionfold within a few hours. This well-established procedure is based on the repetition of heating (denaturing) and cooling (annealing) cycles in the presence of the original DNA molecule, specific DNA primers, dNTPS, and DNA polymerase enzymes. Each cycle produces a doubling of the target DNA segment, leading to an exponential accumulation of the target segment. The generalized procedure involves: 1) processing of the sample to release target DNA molecules into a crude extract, 2) addition of an aqueous solution containing enzymes, buffers, deoxyribonucleotide triphosphates (dNTPS), and two oligonucleotide primers, 3) thermal cycling of the reaction mixture at two or three temperatures (i.e., 94, 72, and 37-54 °C) for typically 20 to 30 cycles, and 4) amplified DNA detection. Intermediate steps are introduced in some assays to incorporate signal-producing and/or surface-binding primers, and to purify the reaction products (e.g., electrophoresis or chromatography). Reaction volumes and times are typically on the order of tens of μ Ls and one to two hours, respectively. PCR-based technology has been applied to a variety of analyses, including environmental and industrial contaminant identification, medical diagnostics, and biological research.

Monolithic microfabrication technology has advanced to the point where a variety of micro-scale components can be made that have electrical, mechanical, optical, chemical, and thermal capabilities. For example, devices have been fabricated that can pump, heat, cool, and mix microliter quantities of solids and liquids. As well, micro-scale optical and electromechanical/chemical physical and chemical sensors have been developed such as fiber optic probes and Lamb-wave sensors. The integration of these devices into systems allows the development of analytical instruments on a micro-scale. The advantages of such integrated devices include the ability to manufacture them in batch quantities with high precision, yet low cost. Their inherent small size also provides significant advantage in that they would be able to perform highly automated *in situ* analyses.

Invention Concept

The invention disclosure herein concerns the application of microinstrumentation to PCR. The small analytical and reaction volumes of PCR make it an ideal diagnostic technique for

implementation on micro-devices. Such a system could contain reservoirs of reagents, agitation and mixing devices to process the target cells, pumps to carry solid and/or fluid reagents to mixing chambers, heaters and coolers to perform the denaturing and annealing cycles, optical and/or electromechanical/chemical sensors to discriminate the reagents and products of the reaction, and separation devices to purify reactants and products. Feedback control via integrated sensors could also be incorporated directly into the system.

Many or all of these devices could be made from microfabrication technology and could process micro- to picoliter volumes. By the selection and integration of appropriate microfabricated devices, a precise and reliable reaction and analysis instrument for PCR-based diagnostics could be devised. A schematic diagram of an example of one such possible system is presented in Figure 1. Several to many of these micro-instruments could be manufactured on a wafer and could run in parallel, allowing the processing and analysis of several target agents and controls. Target DNA detection methodology could include either an optical, electromechanical, electrochemical, or a combination sensing device. Detection signals could be processed and stored with microelectronic devices.





Figure 1. An example of an Integrated microinstrument.

In summary, in this disclosure we describe an integrated microsystem and analytical instrument to perform PCR-based diagnostic methodology. The amplification process from minute sample sizes and reaction volumes, and specific reaction sequence of the PCR technique plays favorably into the micro-device capabilities of on-going microfabrication technology. The development of this integrated micro-PCR system will lead to a highly automated, miniaturized, analytical instrument for *in situ* analyses of a variety of samples.


Inventors:

M. Allen Northrup
923 Creston Rd
Berkeley, CA 94708



Date _____

Richard M. White
350 Panoramic Rd
Berkeley, CA 94708




Date _____

Witnesses:



Date _____



Date _____

COMPLETE THIS FORM USING ADDITIONAL SHEETS AS NECESSARY.

MICROINSTRUMENTATION-BASED POLYMERASE CHAIN REACTION (PCR) DIAGNOSTICS

CAMPUS UNIT OF MAILING ADDRESS

444: 24C

BSAC, EEC, DGT.

PAFESTER

SPONSORS:

PRINCIPAL INVESTIGATOR

روز

247

REFERENCES & COMMENTS

-ELGARDE LING
SECTION 66-1001

THIS DISCLOSURE
~~CONFIDENTIAL~~

105 25

NOT_YET

4075

5. BRIEF ABSTRACT OF INVENTION - ATTACH DETAILED DESCRIPTION

INVENTION CONCERNS APPLICATION OF MICRO-STRUCTURES TO INSTRUMENT FOR AMPLIFICATION OF DNA, ETC. A SPECIFIC EMBODIMENT EMPLOYING THE LAMB-WAVE ULTRASONIC TECHNOLOGY IS SHOWN.

KEYWORDS (OTL USE ONLY)

INVENTION DISCLOSED AND UNDERSTOOD BY

SECRET

DATE RECEIVED \$ 100.00

2019

[illegible]

Source: *Author's calculations.*

Abstract

THE AMERICAN LEGATION

DATE OF ASSESSMENT

The following signatures

— — — — —

UNIVERSITY OF CALIFORNIA, BERKELEY (UCB)
OFFICE OF TECHNOLOGY LICENSING



AGREEMENT CONCERNING DEVELOPMENT OF TECHNOLOGY
AND DISTRIBUTION OF INCOME

Case No. B _____

Name of Technology: Microinstrumentation-Based Polymerase Chain Reaction (PCR),
Diagnostics

Creators: M. Allen Northrup and Richard M. White

Reference: University of California Patent Policy as revised.

1. UCB and Creator(s) desire that the above Technology be licensed by UCB to industry in order that applications and uses of the Technology be made widely available for public use and benefit. Creator therefore assigns to UCB any right, title, and interest he or she may have in the Technology including, but not limited to, patent, copyright, tangible research materials, and semiconductor mask work rights, and assures UCB that he or she has not granted any such rights in Technology to any other person or entity. The term "tangible research materials" refers to research results which are in tangible form as distinct from intangible (or intellectual) property. Examples include integrated circuit chips, computer software, biological organisms, engineering prototypes, engineering drawings and other property which can be physically distributed.
2. UCB shall take such actions as it believes appropriate to make the Technology available for public use and benefit, but shall not be liable for any failure to generate income thereby.
3. Creator agrees to cooperate with UCB to secure and protect UCB's interest and ownership in the Technology, including executing patent assignment and other pertinent documents, giving testimony, and providing pertinent information; provided, however, that if any expenses are incurred by Creators in providing such cooperation, such expenses shall be paid by UCB.

4. Considering the foregoing, Net Royalty Income will be distributed as follows:

CREATOR(S) SHARE: 33 1/3% of Net Royalties
DEPARTMENT SHARE: 50% of Adjusted Net Royalties
UNIVERSITY SHARE: 50% of Adjusted Net Royalties

The academic department(s) (or organized research unit(s)) of the creators are:

Electrical Engineering and Computer Sciences Department and
Berkeley Sensor and Actuator Center

5. "Net royalties" are defined as gross royalties and fees, less 15% thereof for administrative costs, and less the out-of-pocket costs of patenting, protecting, and preserving patent rights, maintaining patents, the licensing of patent and related property rights, and such other costs, taxes, or reimbursements as may be necessary or required by law, and a reserve to cover out-of-pocket expenses which UCB reasonably determines may be incurred in following fiscal years which may not be covered by future royalty revenue. When no longer needed, UCB agrees to distribute the balance of funds reserved according to the formula of paragraph 4 above.
6. "Adjusted Net Royalties" are defined as "Net Royalties," as specified in Paragraph 5 above, less the following deductions to such Net Royalties thereby calculated:

OTL #2

Rev.

BEST AVAILABLE COPY


B

Revolute

Q: any space tests sensible? Phoned Rudi Paulhagen yesterday to inquire.

A.N./BMS:

Could do LW PCR test with existing device by adding on top a foil heater - either as is (try \rightarrow PCR regular tubes first) or attach to a cover slip!



1 membr.
2 reactants
3, 3' xducers

4 cover
5 heater (could combine 4 and 5).

6 heater for the lower (or higher) temp.

7 circulation pattern

\leftarrow To change drive via phase shift \rightarrow to one xducer also possible. Changing freq of one xducer slightly would give a controlled trim on pumping velocity as it varied depth of "pumping" region. \leftarrow (as on 2 pp back)

Pump flow rate: If channel measures $3 \text{ mm} \times 2000 \text{ \AA}$ & $v_{\text{wave}} = 400 \text{ m/s}$, flow rate is

$$3 \times 10^{-1} \text{ cm} \times 2 \times 10^{-3} \text{ cm} \times 4 \times 10^4 \text{ cm/s} = 24 \times 10^{-2} \text{ cm}^3/\text{s} \\ = 0.24 \text{ cm}^3/\text{s} \Rightarrow 240 \mu\text{L/s}.$$

BEST AVAILABLE COPY


C

M. Allington

Device wells

run

Duplicate
PCR - Device
M. Allington



BEST AVAILABLE COPY


Notes (re written)

M. Allington


Device PCR:

- 1) PCR worked in 20-25 μ l rxn volume w/
> 200 μ l oil
- * 2) amplification occurred on both target
and on primers (Primer-Dimers)
probably due to ΔT in device: i.e.,
did not reach 96°C even though
cycler was set to 99°C.

Si:Si₃N₄-Al₂O₃
 3-µm-thick
 20 nm/cm
 Scan rate: 1 µm/sec
 850 → 350 nm




D



M. An. [signature]

I-V \rightarrow temperature
need to calibrate

Resistance vs. Temp.



Next

Foil heater on top (effect of foil heater on reaction?)
 \rightarrow Pump
 \rightarrow ~~Surface~~ Feb Top heater

\hookrightarrow Find 40°C refrigerator (MicroLab?).

To do
 1) different - Surface/volume
 2) - device w/ heater on bottom

Standard device first

ask after
 \hookrightarrow borrow cycles \sim 2 weeks

BEST AVAILABLE COPY

E

Cellus M. All *[signature]*

Try new PCR system
(more Temp forgiving)

142 bp product target as SS M13 From
gag-region of HIV

- 1) Starting target = 10^8 copies in 5 μ l
 $T = 96 - 55$ \downarrow 16-18 cycles
 (works at 88+) is plenty
- 2) primers

old names:	=	new names	
SK 145	=	ph 07	10 μ l/ μ l
SK 431	=	ph 08	

Reaction mixture : (500 μ l)

50 μ l 10 x Buffer w/ MgCl
 " 1 mM dNTPs
 " M13 w/ gag region of HIV

10 μ l = $10^8 \times 10 = 100$ pmoles


10 μ l (same For) ph 07
ph 08 ?

2 1/2 μ l = 10 \times 1.25 μ l/ μ l 12.5
Tag

327.5 ΔH_2O

500 μ l total rxn volume

500.0
 -172.5
 327.5

M. All 

1) re-use voltage (same device) as
on mach 30 ic 3.17 V
at 0.2A 98°C

Do only 20 cycles

A) Standards

10, 10, 20, 20, 30, 30, 40, 40

~150 µl oil (1-8)

B) Device 30 µl w ~ 90 µl oil

1-minute cycles	at 3.17 V
20-1 minute cycles	(A-E) 0.2A

electrophoresis



well-problem
m
pstd 6 1 2 3 4 5 6 7 8 9 10 A B C D D E 4 1 1 1

1a) Had to re-solder device ^{wire connectors} after 2-cycles
fix time ~ 1/2 hour rxn was
at room temp **BEST AVAILABLE COPY**


Results - ① failed product in both
stds and in wells
② wells (and 1) std had
less bright pr or - dimers
③ device provided ~6-5 µl gel
loadings (one was disrupted)

See next
2 pages;

Cont results (photos)

M. Allen

destr. Time = 15 min



T = 1 sec 4.6 3200

M. Allen



121

T = 1 sec 5.6 3200

#1 wound to Mada Ching


BEST AVAILABLE COPY

Cont

Results (photos)
Devia PCE results positive


M. All *[signature]*

elec. T = 15 min



M. All *[signature]* T = 24C
4.4 3200

elec T = 40 min



M. All *[signature]* T = 12C
5.2 3200

BEST AVAILABLE COPY

Cont
Results

M. Allen

Notes (Signal back of several (not all)
results photos with this pen (other (on front)
was ~~not~~ permanent ink)

- PCR (HIV - MSP) worked well in
integrated-heater devices, gel electrophoresis
verified product. Some, but minimal Primase
(esp. due to known fact that device
reaction mixture cycled 1-2 times,
then at R.T. for $\frac{1}{2}$ hr & prior to
20 cycles due to need to re-solder
connections - new rxn mixture (30 μ l)
was added)

- was able to extract ~100% of aqueous
phase with 200 μ l (set at 30 μ l)
pipette & load 5-6 wells of
electrophoresis channel

(*) \rightarrow calculate power consumed in today's
experiment compare to batteries

Other Discussion

Last Tues w/ Ray Manilla
here (Cetus), along w/
Russ Higuchi, Bob Watson, Russ's
technician, myself we tried
homogeneous detection w/ video
CCD over 460 thermal cycles

- pulsed He -laser (ILEE laser
company, Switz) was tried
- \rightarrow see LLNL Book (notebook)
for details

BEST AVAILABLE COPY